SCHEMBL24309475

SCHEMBL24309475

CN(C)c1ccccc1-c1cc(Oc2ccccc2)nc(NS(=O)(=O)c2ccccc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NAT1 P18440 2/20 0.43
▸ GPR39 O43194 1/20 0.42
▸ PGR P06401 2/20 0.41
▸ MAPT P10636 3/20 0.41
▸ GAA P10253 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CACNA1B Q00975 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567129 1.00 TSHR (0.48) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26810957 0.85 TSHR (0.54) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26811084 0.84 MAPT (0.50) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26810948 0.83 TSHR (0.55) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26811062 0.83 TSHR (0.45) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26810953 0.83 TSHR (0.48) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26810785 0.83 TSHR (0.48) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26811053 0.82 TSHR (0.48) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL24309472 0.82 SMN1; SMN2 (0.48) TSHRSMN1; SMN2NAT1GPR39PGR
SCHEMBL26810864 0.82 TSHR (0.48) TSHRSMN1; SMN2NAT1GPR39PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B TSHR 1755/4885SMN1; SMN2 4847/4885NAT1 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback